Teladoc Health stock has fallen sharply over the past few years, yet the current checks suggest the shares may now be trading below what the intrinsic value estimates imply. With the Discounted Cash Flow (DCF) work pointing to a large gap between price and estimated value, investors are weighing that against a long run of weak share price performance.

• Teladoc Health has declined 95.7% over the past 5 years, which means any potential undervaluation today needs to be weighed against a very weak long term return profile.
• Expectations around how Teladoc Health can stabilise and grow its virtual care and mental health platforms may support the valuation, while the current investigation by Pomerantz LLP into potential securities law issues underscores legal and execution risk for the equity story.
• The stock currently scores highly on the broader checks, with Teladoc Health screening as undervalued in 5 of 6 valuation metrics according to the latest assessment, which points to a market price that may not fully reflect the underlying estimates.

The issue now is whether Teladoc Health's weak historical returns and current legal concerns justify the discount to intrinsic value that the DCF work is indicating.

Is Teladoc Health Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here uses projected free cash flows to estimate what Teladoc Health might be worth today. Based on the latest twelve-month numbers, the company generated free cash flow of about $120.2 million, and the model assumes these cash flows recover and grow steadily rather than surge aggressively.

On that basis, the DCF points to an estimated intrinsic value of about $11.62 per share, compared with a current share price that implies roughly a 46.6% discount. The ongoing Pomerantz LLP investigation into potential securities law issues helps explain why the market price may sit well below what the cash flow projections suggest.

Overall, the Discounted Cash Flow work suggests that Teladoc Health stock may be undervalued relative to its projected cash generation.

Our Discounted Cash Flow (DCF) analysis suggests Teladoc Health is undervalued by 46.6%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Is Teladoc Health a Bargain on Sales?

P/S is a useful cross check for Teladoc Health because the company is still working toward stronger profitability while already generating meaningful revenue.

Teladoc Health trades on a P/S of about 0.5x. This is well below the Healthcare Services industry average of around 2.9x and also below the peer average of about 3.1x. The model based fair P/S multiple for the stock is 1.7x, which reflects what might be expected given factors such as its margins, growth profile, size and risk. The gap between the current 0.5x and the 1.7x fair multiple suggests the market is pricing Teladoc Health’s revenue stream at a sizeable discount to what these benchmarks indicate.

That discount sits alongside the legal and execution questions already raised, so any P/S based opportunity still needs to be balanced against those risks.

On the P/S multiple, Teladoc Health stock currently screens as undervalued compared with both the industry and the fair value benchmark.

The Teladoc Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Teladoc Health's valuation puzzle leaves off by explaining what would need to happen to growth, margins and earnings for the stock to be worth materially more or less than today's price. Each one presents Teladoc Health's fair value as a thesis about the business that you can revisit over time, rather than a one off snapshot, and they sit on Simply Wall St's Community page.

Community views on Teladoc Health split sharply, with one camp focused on cash generation and another worried about pressure on margins and demand.

Bull case: 59% undervalued

"The BetterHelp Insurance Pivot: BetterHelp is transitioning from out-of-pocket subscription payments to insurance reimbursement (live in 30+ states with over 150 million contracted lives), creating a higher-margin, recurring revenue tailwind..."

Bear case: 13% overvalued

"Margin pressures are likely to intensify due to lower unit economics as BetterHelp's insurance-based mental health revenues scale, since insurance reimbursement yields significantly lower gross profits than the legacy cash pay business and requires ongoing operational investment, threatening segment-level and consolidated profitability for multiple years..."

Do you think there's more to the story for Teladoc Health? Head over to our Community to see what others are saying!

The Bottom Line

The Discounted Cash Flow (DCF) work points to Teladoc Health as undervalued, and the P/S checks tell a similar story on revenue. Both signals suggest the current market price embeds a lot of caution around Teladoc Health's outlook and risks. The key question now is whether the company can sustain cash generation and improve profitability fast enough for that discount to close, or whether ongoing legal and execution concerns mean the low valuation is justified and the stock remains a possible value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.